Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies.
Blanquicett C, Johnson MR, Heslin M, Diasio RB. Blanquicett C, et al. Anal Biochem. 2002 Apr 15;303(2):209-14. doi: 10.1006/abio.2001.5570. Anal Biochem. 2002. PMID: 11950223 No abstract available.
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Blanquicett C, et al. Mol Cancer Ther. 2002 Oct;1(12):1139-45. Mol Cancer Ther. 2002. PMID: 12481438
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.
Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR. Steg A, et al. J Mol Diagn. 2006 Feb;8(1):76-83. doi: 10.2353/jmoldx.2006.040402. J Mol Diagn. 2006. PMID: 16436637 Free PMC article.
In addition, several genes were significantly (P < 0.025) down-regulated in OEA, including cyclin E2, Porcupine, c-Myc, and Axin 2 (4.8-, 3.6-, 2.9-, and 1.9-fold, respectively). ...

In addition, several genes were significantly (P < 0.025) down-regulated in OEA, including cyclin E2, Porcupine, c-Myc, and Axin 2

Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.
Guarcello V, Blanquicett C, Naguib FN, El Kouni MH. Guarcello V, et al. Cancer Chemother Pharmacol. 2008 Jun;62(1):85-96. doi: 10.1007/s00280-007-0578-5. Epub 2007 Sep 1. Cancer Chemother Pharmacol. 2008. PMID: 17805539
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR. Blanquicett C, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8773-81. doi: 10.1158/1078-0432.CCR-05-0627. Clin Cancer Res. 2005. PMID: 16361565
In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J. Fanciullino R, et al. Among authors: blanquicett c. Br J Cancer. 2007 Oct 8;97(7):919-26. doi: 10.1038/sj.bjc.6603970. Epub 2007 Sep 11. Br J Cancer. 2007. PMID: 17848948 Free PMC article.
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B. Ciccolini J, et al. Ther Drug Monit. 2006 Oct;28(5):678-85. doi: 10.1097/01.ftd.0000245771.82720.c7. Ther Drug Monit. 2006. PMID: 17038885
Increased peptidylarginine deiminase type II in hypoxic astrocytes.
Sambandam T, Belousova M, Accaviti-Loper MA, Blanquicett C, Guercello V, Raijmakers R, Nicholas AP. Sambandam T, et al. Biochem Biophys Res Commun. 2004 Dec 24;325(4):1324-9. doi: 10.1016/j.bbrc.2004.10.173. Biochem Biophys Res Commun. 2004. PMID: 15555572
Oxidative stress modulates PPAR gamma in vascular endothelial cells.
Blanquicett C, Kang BY, Ritzenthaler JD, Jones DP, Hart CM. Blanquicett C, et al. Free Radic Biol Med. 2010 Jun 15;48(12):1618-25. doi: 10.1016/j.freeradbiomed.2010.03.007. Epub 2010 Mar 17. Free Radic Biol Med. 2010. PMID: 20302927 Free PMC article.
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.
Launay M, Ciccolini J, Fournel C, Blanquicett C, Dupuis C, Fakhry N, Duffaud F, Salas S, Lacarelle B. Launay M, et al. Among authors: blanquicett c. Clin Cancer Drugs. 2017;4(2):122-128. doi: 10.2174/2212697x04666170817123425. Clin Cancer Drugs. 2017. PMID: 29682445 Free PMC article.
18 results
Jump to page
Feedback